Roivant Sciences (Roivant Sciences) Debt-to-Equity : 0.08 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Debt-to-Equity?

Roivant Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $56.2 Mil. Roivant Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $450.4 Mil. Roivant Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6,089.8 Mil. Roivant Sciences's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Roivant Sciences's Debt-to-Equity or its related term are showing as below:

ROIV' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.26 Max: 0.54
Current: 0.08

During the past 3 years, the highest Debt-to-Equity Ratio of Roivant Sciences was 0.54. The lowest was 0.08. And the median was 0.26.

ROIV's Debt-to-Equity is ranked better than
63.31% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs ROIV: 0.08

Roivant Sciences Debt-to-Equity Historical Data

The historical data trend for Roivant Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Debt-to-Equity Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-Equity

0.14

0.17

0.42

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										0.50	0.42	0.54	0.53	0.08

Competitive Comparison of Roivant Sciences's Debt-to-Equity

For the Biotechnology subindustry, Roivant Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Debt-to-Equity falls into.

Roivant Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Roivant Sciences's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(52.413	+	428.991)	/	1157.766
	=	0.42

Roivant Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(56.183	+	450.396)	/	6089.763
	=	0.08

Roivant Sciences (NAS:ROIV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Roivant Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences (Roivant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

87S:Germany

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Executives

Eric Venker	officer: President & COO	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester	director	C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold	director	6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp	10 percent owner, other: Director by Deputization	888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar	officer: Chief Accounting Officer	C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p.	10 percent owner	AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik	officer: CFO	SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy	director	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000